Pharmacokinetics
The lower limit of quantification for DS‐1205a (free form of DS‐1205c) was 5 ng/ml. Time courses of mean plasma DS‐1205a concentrations for each DS‐1205c dose during DS‐1205c monotherapy (Cycle 0, Days 1 and 7) and DS‐1205c plus gefitinib combination therapy (Cycles 1 and 2, Day 1) are shown in Figure Time course of mean plasma DS‐1205a concentrations for each DS‐1205c dose during DS‐1205c monotherapy (Cycle 0 Day 1 [A] and Cycle 0 Day 7 [B]) and DS‐1205c plus gefitinib combination therapy (Cycle 1 Day 1 [C] and Cycle 2 Day 1 [D]). The lower limit of quantitation (5 ng/ml) is indicated by a dotted line. Error bars show standard deviation.Pharmacokinetics of DS‐1205a (free form of DS‐1205c) for DS‐1205c monotherapy (Cycle 0) and DS‐1205c/gefitinib combination therapy (Cycles 1 and 2)Abbreviation: BID, twice daily.The upper limits of 90% CIs for the slope of the power model were less than 1 for all PK parameters of Summary of results for pharmacokinetic parameters using a power model
Although the mean 